http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease
-
DiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019
-
DiaMedica Therapeutics to Report Second Quarter 2019 Financials and Provide a Business Update August 13, 2019
-
DiaMedica Therapeutics Inc. (DMAC) Reports Interim Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants
-
DiaMedica Therapeutics Announces Interim Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants
-
DiaMedica Therapeutics to Report First Quarter 2019 Financials and Provide an Update on Development Programs on May 14, 2019
-
DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting
-
DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
-
DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders
-
UPDATE -- DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
-
DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease

